Literature DB >> 35791853

Barriers and Facilitators to Chronic Red Cell Transfusion Therapy in Pediatric Sickle Cell Anemia.

Alyssa M Schlenz1, Shannon M Phillips2, Martina Mueller2,3, Cathy L Melvin3, Robert J Adams4, Julie Kanter5.   

Abstract

Background: Chronic red cell transfusion (CRCT) therapy is one of a few effective disease-modifying therapies for children with sickle cell anemia (SCA). CRCT is recommended for primary and secondary stroke prevention for at-risk children with SCA and is sometimes used for other disease-related complications. However, CRCT can be resource- and time-intensive for patients/families, providers, and organizations. This study was conducted to provide a comprehensive, multilevel examination of barriers and facilitators to transfusion therapy in children with SCA from health care provider and caregiver perspectives.
Methods: A qualitative descriptive approach was used to conduct key informant interviews in a sample of 26 caregivers and 25 providers across the United States. Interviews were analyzed using directed content analysis with the Multilevel Ecological Model of Health as an initial coding framework and the constant comparison method.
Results: Ten barrier themes and 10 facilitator themes emerged across all ecological levels. Themes most commonly occurred on the patient and organizational levels. Key barriers themes included Logistical Challenges, Obtaining and Maintaining Venous Access, Alloantibodies/Alloimmunization and Reactions, and Iron Overload and Adherence to Chelation Therapy. Key facilitator themes included Nursing and Non-nursing Staff Support, Positive Child/Family Experiences, Logistical Help and Social Resources, Blood Bank and Access to Blood, and Transfusion-Specific Resources. Discussion: The comprehensive understanding of multilevel barriers and facilitators to transfusion therapy, including the role of nursing, in children with SCA can inform strategies to improve CRCT for patients/families and providers and can also be applied by organizations seeking to implement transfusion services for SCA.

Entities:  

Keywords:  multilevel ecological model; qualitative; sickle cell anemia; transfusion

Mesh:

Year:  2022        PMID: 35791853      PMCID: PMC9462376          DOI: 10.1177/27527530211073874

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol Nurs        ISSN: 2752-7530


  22 in total

Review 1.  Whatever happened to qualitative description?

Authors:  M Sandelowski
Journal:  Res Nurs Health       Date:  2000-08       Impact factor: 2.228

2.  Three approaches to qualitative content analysis.

Authors:  Hsiu-Fang Hsieh; Sarah E Shannon
Journal:  Qual Health Res       Date:  2005-11

3.  Blood bank management of sickle cell patients at comprehensive sickle cell centers.

Authors:  Araba Afenyi-Annan; Monte S Willis; Thomas R Konrad; Richard Lottenberg
Journal:  Transfusion       Date:  2007-11       Impact factor: 3.157

Review 4.  A systematic review of barriers and interventions to improve appropriate use of therapies for sickle cell disease.

Authors:  Carlton Haywood; Mary Catherine Beach; Sophie Lanzkron; John J Strouse; Renee Wilson; Haeseong Park; Catherine Witkop; Eric B Bass; Jodi B Segal
Journal:  J Natl Med Assoc       Date:  2009-10       Impact factor: 1.798

5.  Health-related quality of life in children with sickle cell anemia: impact of blood transfusion therapy.

Authors:  Lauren M Beverung; John J Strouse; Monica L Hulbert; Kathleen Neville; Robert I Liem; Baba Inusa; Beng Fuh; Allison King; Emily Riehm Meier; James Casella; Michael R DeBaun; Julie A Panepinto
Journal:  Am J Hematol       Date:  2015-02       Impact factor: 10.047

6.  Barriers to care and quality of primary care services in children with sickle cell disease.

Authors:  Eufemia Jacob; Courtney Childress; Joana Duran Nathanson
Journal:  J Adv Nurs       Date:  2015-09-15       Impact factor: 3.187

7.  Red cell exchange for patients with sickle cell disease: an international survey of current practices.

Authors:  Matthew S Karafin; Jeanne E Hendrickson; Haewon C Kim; Aisha Kuliya-Gwarzo; Monica B Pagano; Ajay Perumbeti; Patricia A Shi; Yvette C Tanhehco; Jennifer Webb; Edward Wong; Quentin Eichbaum
Journal:  Transfusion       Date:  2020-06-24       Impact factor: 3.157

Review 8.  Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.

Authors:  Barbara P Yawn; George R Buchanan; Araba N Afenyi-Annan; Samir K Ballas; Kathryn L Hassell; Andra H James; Lanetta Jordan; Sophie M Lanzkron; Richard Lottenberg; William J Savage; Paula J Tanabe; Russell E Ware; M Hassan Murad; Jonathan C Goldsmith; Eduardo Ortiz; Robinson Fulwood; Ann Horton; Joylene John-Sowah
Journal:  JAMA       Date:  2014-09-10       Impact factor: 56.272

9.  American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support.

Authors:  Stella T Chou; Mouaz Alsawas; Ross M Fasano; Joshua J Field; Jeanne E Hendrickson; Jo Howard; Michelle Kameka; Janet L Kwiatkowski; France Pirenne; Patricia A Shi; Sean R Stowell; Swee Lay Thein; Connie M Westhoff; Trisha E Wong; Elie A Akl
Journal:  Blood Adv       Date:  2020-01-28

10.  Patient and family experience with chronic transfusion therapy for sickle cell disease: A qualitative study.

Authors:  Lauren M Hawkins; Cynthia B Sinha; Diana Ross; Marianne E M Yee; Maa-Ohui Quarmyne; Lakshmanan Krishnamurti; Nitya Bakshi
Journal:  BMC Pediatr       Date:  2020-04-18       Impact factor: 2.125

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.